1-phenyl-2-decanoylamino-3-morpholino-1-propanol and Pancreatic Neoplasms

Research

Authors	Studies
Cheng, B; Gong, L; Jing, Y; Tang, X; Wu, GJ; Xu, M; Yang, B; Zheng, P	1
Hui, PP; Ma, JL; Wang, N; Wang, T; Wei, J	1
Barth, BM; Cabot, MC; Cheng, H; DiVittore, NA; Fox, TE; Fritz, JL; Heakal, Y; Jiang, Y; Kaiser, JM; Kester, M; Shanmugavelandy, SS; Staveley-O'Carroll, KF; Tagaram, HR; Tran, MA	1

3 other study(ies) available for 1-phenyl-2-decanoylamino-3-morpholino-1-propanol and Pancreatic Neoplasms

Article	Year
Bortezomib-induced apoptosis in cultured pancreatic cancer cells is associated with ceramide production. Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Ceramides; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase Kinase 5; Morpholines; Pancreatic Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Pyrazines	2014
The glucosylceramide synthase inhibitor PDMP sensitizes pancreatic cancer cells to MEK/ERK inhibitor AZD-6244. Biochemical and biophysical research communications, 2015, Jan-16, Volume: 456, Issue:3 Topics: Apoptosis; Benzimidazoles; Cell Line, Tumor; Ceramides; Drug Resistance, Neoplasm; Enzyme Inhibitors; Glucosyltransferases; Humans; Morpholines; Pancreatic Neoplasms; Protein Kinase Inhibitors	2015
Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer. Cancer biology & therapy, 2011, Oct-01, Volume: 12, Issue:7 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Ceramides; Deoxycytidine; Drug Carriers; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Female; Gemcitabine; Glucosyltransferases; Humans; Liposomes; MAP Kinase Signaling System; Mice; Mice, Nude; Morpholines; Nanoparticles; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Xenograft Model Antitumor Assays	2011